23:10 , Oct 6, 2017 |  BioCentury  |  Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
22:01 , Apr 19, 2017 |  BC Extra  |  Financial News

Agios, Audentes price follow-ons

Cancer company Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and gene therapy and rare diseases play Audentes Therapeutics Inc. (NASDAQ:BOLD) raised a total of more than $325 million in follow-ons. Agios raised $250 million through the sale of...
07:00 , Jul 20, 2016 |  BC Extra  |  Top Story

Audentes inches up after pricing $75M IPO

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) added $0.13 to $15.13 on its first day of trading Wednesday after raising $75 million through the sale of 5 million shares at $15 in an IPO. The...